Welcome to our dedicated page for Haemonetics Mass SEC filings (Ticker: HAE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Haemonetics Corporation (NYSE: HAE) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Massachusetts corporation and NYSE-listed issuer, Haemonetics reports material events, financial results and shareholder matters through forms such as Form 8-K.
Recent 8-K filings show several key categories of information. Under Item 2.02, Haemonetics furnishes press releases announcing quarterly financial results, including results for specific fiscal quarters and the first half of a fiscal year. These filings clarify that the furnished earnings releases are not deemed filed for purposes of Section 18 of the Exchange Act but provide investors with detailed financial updates.
Another important filing type is the Item 8.01 Other Events 8-K, such as the report dated January 9, 2026 describing Haemonetics’ acquisition of Vivasure Medical Limited. That filing outlines the terms of the transaction, including upfront consideration, contingent payments based on sales growth and milestone achievements, and the use of available cash on hand to finance the acquisition. It also references the related press release furnished as an exhibit.
Haemonetics’ SEC filings also document shareholder meeting results. An 8-K under Item 5.07 details the outcomes of votes at the 2025 Annual Meeting of Shareholders, including the election of directors, advisory approval of executive compensation and ratification of the independent registered public accounting firm.
On Stock Titan, these filings are updated as they appear on EDGAR, and AI-powered tools can help summarize long documents, highlight key sections and surface items such as earnings disclosures, acquisition terms and shareholder vote results. This allows users to review Haemonetics’ regulatory history, understand significant corporate events and see how the company communicates financial and governance information to the market.
Haemonetics Corporation furnished a press release announcing financial results for the second quarter ended September 27, 2025 and the first half of fiscal 2026. The release is attached to a Form 8‑K as Exhibit 99.1 under Item 2.02. The company notes this information, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act, and is not incorporated by reference. The filing also includes the Inline XBRL cover page file as Exhibit 104.
Haemonetics (HAE) disclosed an insider Form 4 for its EVP, Chief Commercial Officer. On 10/31/2025, 145 shares of common stock were withheld for taxes upon RSU vesting (code F) at $50.01 per share. Following this transaction, the reporting person directly beneficially owns 12,811 shares. This total includes unvested RSUs and 24 shares acquired under the company’s Employee Stock Purchase Plan on October 31, 2025.
Haemonetics insider transaction summary: Laurie A. Miller, SVP, Human Resources at Haemonetics Corp (HAE), reported a Form 4 showing a tax-withholding disposition tied to the vesting of restricted stock units. On 09/17/2025, 238 shares were disposed (transaction code F) at a price of $49.95 per share to satisfy tax obligations related to vested RSUs. After that transaction, Ms. Miller beneficially owned 28,925 shares, which the filing notes includes unvested RSUs previously reported. The Form 4 was signed by attorney-in-fact Thomas V. Powers on 09/24/2025.